HGEN Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 21.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Humanigen Insider Trading History Chart

This chart shows the insider buying and selling history at Humanigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Humanigen Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 01/4/2024 10:06 PM ET

This chart shows the closing price history over time for HGEN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Humanigen Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Humanigen (NASDAQ:HGEN)

4.55% of Humanigen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at HGEN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
Humanigen logo
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Read More on Humanigen

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

2,063,600 shs

Average Volume

3,262,400 shs

Market Capitalization

$24,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A